These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37242781)

  • 1. Thermodynamic Modeling of the Amorphous Solid Dispersion-Water Interfacial Layer and Its Impact on the Release Mechanism.
    Dohrn S; Kyeremateng SO; Bochmann E; Sobich E; Wahl A; Liepold B; Sadowski G; Degenhardt M
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Low-Molecular-Weight Excipients on the Phase Behavior of PVPVA64 Amorphous Solid Dispersions.
    Lehmkemper K; Kyeremateng SO; Degenhardt M; Sadowski G
    Pharm Res; 2018 Jan; 35(1):25. PubMed ID: 29305717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Physical Stability of PVP- and PVPVA-Amorphous Solid Dispersions.
    Lehmkemper K; Kyeremateng SO; Heinzerling O; Degenhardt M; Sadowski G
    Mol Pharm; 2017 Jan; 14(1):157-171. PubMed ID: 28043133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solvent influence on the phase behavior and glass transition of Amorphous Solid Dispersions.
    Dohrn S; Luebbert C; Lehmkemper K; Kyeremateng SO; Degenhardt M; Sadowski G
    Eur J Pharm Biopharm; 2021 Jan; 158():132-142. PubMed ID: 33212185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical stability of API/polymer-blend amorphous solid dispersions.
    Lehmkemper K; Kyeremateng SO; Bartels M; Degenhardt M; Sadowski G
    Eur J Pharm Biopharm; 2018 Mar; 124():147-157. PubMed ID: 29269154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
    Indulkar AS; Lou X; Zhang GGZ; Taylor LS
    Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Explaining the Release Mechanism of Ritonavir/PVPVA Amorphous Solid Dispersions.
    Krummnow A; Danzer A; Voges K; Dohrn S; Kyeremateng SO; Degenhardt M; Sadowski G
    Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutual Impact of Phase Separation/Crystallization and Water Sorption in Amorphous Solid Dispersions.
    Luebbert C; Wessner M; Sadowski G
    Mol Pharm; 2018 Feb; 15(2):669-678. PubMed ID: 29309155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Polymer Type and Relative Humidity on the Long-Term Physical Stability of Amorphous Solid Dispersions.
    Lehmkemper K; Kyeremateng SO; Heinzerling O; Degenhardt M; Sadowski G
    Mol Pharm; 2017 Dec; 14(12):4374-4386. PubMed ID: 29050468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissolution Mechanisms of Amorphous Solid Dispersions: Application of Ternary Phase Diagrams To Explain Release Behavior.
    Deac A; Luebbert C; Qi Q; Courtney RM; Indulkar AS; Gao Y; Zhang GGZ; Sadowski G; Taylor LS
    Mol Pharm; 2024 Apr; 21(4):1900-1918. PubMed ID: 38469754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of humidity on the phase behavior of API/polymer formulations.
    Prudic A; Ji Y; Luebbert C; Sadowski G
    Eur J Pharm Biopharm; 2015 Aug; 94():352-62. PubMed ID: 26117187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of Water-Induced Amorphous Phase Separation in Amorphous Solid Dispersions via Raman Mapping.
    Krummnow A; Danzer A; Voges K; Kyeremateng SO; Degenhardt M; Sadowski G
    Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase behavior of pharmaceutically relevant polymer/solvent mixtures.
    Dohrn S; Luebbert C; Lehmkemper K; Kyeremateng SO; Degenhardt M; Sadowski G
    Int J Pharm; 2020 Mar; 577():119065. PubMed ID: 31988034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moisture-induced phase separation and recrystallization in amorphous solid dispersions.
    Luebbert C; Sadowski G
    Int J Pharm; 2017 Oct; 532(1):635-646. PubMed ID: 28867448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Influencing the Crystallization-Onset Time of Metastable ASDs.
    Wolbert F; Fahrig IK; Gottschalk T; Luebbert C; Thommes M; Sadowski G
    Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35214002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can Pure Predictions of Activity Coefficients from PC-SAFT Assist Drug-Polymer Compatibility Screening?
    Pavliš J; Mathers A; Fulem M; Klajmon M
    Mol Pharm; 2023 Aug; 20(8):3960-3974. PubMed ID: 37386723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailored ASD destabilization - Balancing shelf life stability and dissolution performance with hydroxypropyl cellulose.
    Luebbert C; Stoyanov E
    Int J Pharm X; 2023 Dec; 5():100187. PubMed ID: 37396620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choosing Appropriate Solvents for ASD Preparation.
    Luebbert C; Real D; Sadowski G
    Mol Pharm; 2018 Nov; 15(11):5397-5409. PubMed ID: 30335401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congruent release of drug and polymer: A "sweet spot" in the dissolution of amorphous solid dispersions.
    Saboo S; Mugheirbi NA; Zemlyanov DY; Kestur US; Taylor LS
    J Control Release; 2019 Mar; 298():68-82. PubMed ID: 30731151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The step-wise dissolution method: An efficient DSC-based protocol for verification of predicted API-polymer compatibility.
    Mathers A; Pechar M; Hassouna F; Fulem M
    Int J Pharm; 2023 Dec; 648():123604. PubMed ID: 37981251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.